Abilita Bio Overview
- Founded
-
2014
- Status
-
Private
- Latest Deal Type
-
Grant
- Investors
-
3
Abilita Bio General Information
Description
Owner and operator of an innovation-driven biotechnology company intended to develop drugs targeting membrane proteins. The company's services mainly focus on discovering and developing therapeutic drugs and technologies to enable discovery and development of drugs targeting membrane proteins including G protein-coupled receptors (GPCRs) and ion channels through the application of its enabled membrane proteins technology platform, enabling clients to have access to tool receptors for antibody discovery and a technical service through the generation of enabled membrane proteins.
Contact Information
Website
www.abilitabio.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Primary Office
- 3210 Merryfield Row
- San Diego, CA 92121
- United States
Abilita Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 20-Sep-2016 | Completed | Startup | |||
| 3. Grant | 01-Jan-2016 | 00000 | Completed | Startup | ||
| 2. Accelerator/Incubator | 01-Jan-2015 | Completed | Startup | |||
| 1. Angel (individual) | 01-Jan-2015 | Completed | Startup |
Abilita Bio Patents
Abilita Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017259821-A1 | Methods and platform for preparing multispanning membrane proteins | Pending | 04-May-2016 | 0000000000 | |
| EP-3452516-A1 | Methods and platform for preparing multispanning membrane proteins | Pending | 04-May-2016 | 0000000000 | |
| EP-3452516-A4 | Methods and platform for preparing multispanning membrane proteins | Pending | 04-May-2016 | 0000000000 | |
| JP-2019527065-A | Methods and platforms for preparing multiple transmembrane proteins | Pending | 04-May-2016 | 0000000000 | |
| US-10845367-B2 | Modified multispanning membrane polypeptides and methods of use thereof to screen therapeutic agents | Active | 04-May-2016 | G01N33/577 | 00 |
Abilita Bio Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Mauro Mileni Ph.D | Founder & Chief Executive Officer | ||
| James Schmidt | Chief Financial Officer | ||
| Rosario Billetta | Chief Technology Officer |
Abilita Bio Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| National Cancer Institute | Government | 000 0000 | 000000 0 | ||
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | 000 0000 | 000000 0 |